Knotus Co Ltd
KOSDAQ:278650
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Knotus Co Ltd
Other Current Assets
Knotus Co Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Other Current Assets
₩1.5B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Other Current Assets
₩149.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Other Current Assets
₩1.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Other Current Assets
₩1.4B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
8%
|
CAGR 10-Years
29%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Other Current Assets
₩10.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Other Current Assets
₩8.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
25%
|
|
Knotus Co Ltd
Glance View
KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.
See Also
What is Knotus Co Ltd's Other Current Assets?
Other Current Assets
1.5B
KRW
Based on the financial report for Dec 31, 2024, Knotus Co Ltd's Other Current Assets amounts to 1.5B KRW.
What is Knotus Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-21%
Over the last year, the Other Current Assets growth was 73%. The average annual Other Current Assets growth rates for Knotus Co Ltd have been -42% over the past three years , -21% over the past five years .
